Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 3,689	$ 374
Accounts receivable		3
Research and development tax credit receivable		549
Note receivables, net	6,213
Prepaid expenses and other current assets	454	575
Total current assets	10,356	1,501
Property, plant and equipment, net		180
Right-of-use assets, net	0	607
Total assets	10,356	2,288
Current liabilities
Accounts payable and accrued expenses	675	4,603
Lease liabilities, current		271
Notes payable, net		928
Deferred revenue		108
Total current liabilities	675	5,910
Lease liabilities, non-current		312
Total liabilities	675	6,222
Contingencies (Note 9)
Stockholders' equity / (deficit):
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 26,411.5 and 0 shares issued and outstanding, at June 30, 2026 and December 31, 2025, respectively
Common stock, par value $0.0001 per share, 5,000,000,000 shares authorized, 25,682,643 and 6,839,689 shares issued and outstanding, at June 30, 2026 and December 31, 2025, respectively	3	1
Additional paid-in capital	157,433	124,772
Accumulated other comprehensive loss		(3,578)
Accumulated deficit	(147,755)	(125,129)
Total stockholders' equity / (deficit)	9,681	(3,934)
Total liabilities and stockholders' equity / (deficit)	$ 10,356	$ 2,288

The amount of research and development tax credit receivable as on balance sheet date.

No definition available.

Name:	smtk_ResearchAndDevelopmentTaxCredit
Namespace Prefix:	smtk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.